Ina Rhee

4.8k citations

14 papers · 2.3k indexed · 1 hit paper · h-index 12

Impact in

Molecular Biology top 5%
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- RNA modifications and cancer
- Genomics and Chromatin Dynamics
- Histone Deacetylase Inhibitors Research
Oncology top 5%
- Cancer Immunotherapy and Biomarkers

Papers in

Immunology 5
- Immunotherapy and Immune Responses 4
Oncology 6
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 2
- Colorectal Cancer Treatments and Studies 2

Co-authors: Stephen B. Baylin Bert Vogelstein Kenneth W. Kinzler Kurtis E. Bachman Kornel E. Schuebel Ben Ho Park Christoph Lengauer Kam-Wing Jair
Journals: Journal of Clinical Oncology (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Nature (2 papers)The Oncologist (2 papers)Magnetic Resonance in Medicine (1 paper)
Partner nations: United States France Australia

In The Last Decade

Ina Rhee

14 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells 2002 · 979 citations

Peers

Countries citing papers authored by Ina Rhee

Since Specialization

Citations

This map shows the geographic impact of Ina Rhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ina Rhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ina Rhee more than expected).

Fields of papers citing papers by Ina Rhee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ina Rhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ina Rhee. The network helps show where Ina Rhee may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ina Rhee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ina Rhee Line = papers co-authored together Ina Rhee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Journal for ImmunoTherapy of Cancer ·Naiyer A. Rizvi, Foluso O. Ademuyiwa, Z. Alexander Cao, Helen X Chen, Robert L. Ferris, Sarah B. Goldberg, Matthew D. Hellmann, Ranee Mehra, Ina Rhee, Jong Chul Park, Harriet M. Kluger, Hussein A. Tawbi, Ryan J. Sullivan	2023	24
2	Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Colin D. Weekes, Lee S. Rosen, Anna Capasso, Kit Man Wong, Weilan Ye, Maria Anderson, Bruce McCall, Jill Fredrickson, Eric Wakshull, Steve Eppler, Noël Montgrain, Rupal Desai, Mahrukh Huseni, Priti S. Hegde, Tony Pourmohamad, Ina Rhee, Alberto Bessudo	2018	15
3	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy Journal of Clinical Oncology ·F. Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean‐Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David C. Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S. Chen, Jedd D. Wolchok	2018	242
4	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer The Oncologist ·Joachim von Pawel, David R. Spigel, Thomas J. Ervin, György Losonczy, Fabrice Barlési, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti S. Hegde, Weilan Ye, Mirlan I. Asanaliev, Ilsung Chang, Ina Rhee, Martin Reck	2018	19
5	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer The Oncologist ·Rocio García‐Carbonero, Eric Van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall C. Tebbutt, Fadi Braiteh, Guillem Argilés, Zev A. Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti S. Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert I. Hurwitz	2017	23
6	Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population Magnetic Resonance in Medicine ·Jill Fredrickson, Natalie J. Serkova, Shelby K. Wyatt, Richard A.D. Carano, Andrea Pirzkall, Ina Rhee, Lee S. Rosen, Alberto Bessudo, Colin D. Weekes, Alex de Crespigny	2016	12
7	A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. Journal of Clinical Oncology ·Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian, Laura Q.M. Chow, Grant A. McArthur, Todd M. Bauer, Stephen V. Liu, Shahneen Sandhu, Frank Tsai, Jeong Kim, Eric Stefanich, Chi‐Chung Li, Houston Gilbert, Bruce McCall, Maria Anderson, Mahrukh Huseni, Ina Rhee, Lillian L. Siu, Michael S. Gordon	2016	55
8	Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models Journal for ImmunoTherapy of Cancer ·Mahrukh Huseni, Klára Tótpál, Changchun Du, PC Simamoto, Jing Zhu, Deepali Rishipathak, Erin McNamara, Ломшаков Михаил Георгиевич, Priti S. Hegde, Ina Rhee, Lisa A. Damico‐Beyer, Jeong Kim	2014	1
9	Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models Journal for ImmunoTherapy of Cancer ·Mahrukh Huseni, Klára Tótpál, Changchun Du, PC Simamoto, Jing Zhu, Deepali Rishipathak, Erin McNamara, Ломшаков Михаил Георгиевич, Priti S. Hegde, Ina Rhee, Lisa A. Damico‐Beyer, Jeong Kim	2014	1
10	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology ·Daniel C. Cho, Jeffrey A. Sosman, Mario Sznol, Michael S. Gordon, Antoine Hollebecque, Omid Hamid, David F. McDermott, Jean‐Pierre Delord, Ina Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Funke, Gregg Fine, Thomas Powles	2013	84
11	De novo CpG Island Methylation in Human Cancer Cells Cancer Research ·Kam-Wing Jair, Kurtis E. Bachman, Hiromu Suzuki, Angela H. Ting, Ina Rhee, Ray-Whay Chiu Yen, Stephen B. Baylin, Kornel E. Schuebel	2006	159
12	Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene Cancer Cell ·Kurtis E. Bachman, Ben Ho Park, Ina Rhee, Harith Rajagopalan, James G. Herman, Stephen B. Baylin, Kenneth W. Kinzler, Bert Vogelstein	2003	333
13	DNMT1 and DNMT3b cooperate to silence genes in human cancer cells Nature ·Ina Rhee, Kurtis E. Bachman, Ben Ho Park, Kam-Wing Jair, Ray-Whay Chiu Yen, Kornel E. Schuebel, Hengmi Cui, Andrew P. Feinberg, Christoph Lengauer, Kenneth W. Kinzler, Stephen B. Baylin, Bert Vogelstein Hit paper breakdown →	2002	979
14	CpG methylation is maintained in human cancer cells lacking DNMT1 Nature ·Ina Rhee, Kamwing Jair, Ray-Whay Chiu Yen, Christoph Lengauer, James G. Herman, Kenneth W. Kinzler, Bert Vogelstein, Stephen B. Baylin, Kornel E. Schuebel	2000	351

About Ina Rhee

Ina Rhee is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 14 papers that have together received 2.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), Epigenetics and DNA Methylation (4 papers), Cancer-related gene regulation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), RNA modifications and cancer (2 papers), CAR-T cell therapy research (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Molecular Biology (1.8k citations), Oncology (520 citations), Cancer Research (273 citations), Genetics (310 citations) and Immunology (232 citations). Ina Rhee has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Stephen B. Baylin, Bert Vogelstein, Kenneth W. Kinzler, Kurtis E. Bachman, Kornel E. Schuebel, Ben Ho Park, Christoph Lengauer, Kam-Wing Jair, Ray-Whay Chiu Yen and Hengmi Cui. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Nature, The Oncologist and Magnetic Resonance in Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact